PPLPHARMA vs WOCKPHARMA: Stock Comparison

Piramal Pharma Limited vs Wockhardt Ltd

Live data: 22 July 2026, 3:01 PM IST • Source: NSE and company filings

Wockhardt Ltd is the larger company by market capitalisation. Piramal Pharma Limited shows a lower P/E and a higher dividend yield, while Wockhardt Ltd shows a higher ROE, faster revenue growth and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Piramal Pharma Limited and Wockhardt Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, PPLPHARMA is more favourable on 3 of 13 scored metrics and WOCKPHARMA on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
WOCKPHARMA is the larger company
₹30,362 Cr vs ₹23,554 Cr
P/E Ratio
PPLPHARMA has a lower P/E
-75.43x vs 144.46x
P/B Ratio
PPLPHARMA has a lower P/B
3.01x vs 6.23x
EPS
WOCKPHARMA has higher earnings per share
₹13.1 vs ₹-2.45
Dividend Yield
PPLPHARMA has a higher dividend yield
0.08% vs 0%
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs -0.1%
Qtr Sales Growth
WOCKPHARMA has stronger quarterly sales growth
29.9% vs -0.08%
Qtr Profit Growth
WOCKPHARMA has stronger quarterly profit growth
688% vs -25%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricPPLPHARMAWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricPPLPHARMAWOCKPHARMA
Live Price₹177.2₹1,866.9
Day Change-4.12%-1.55%
Volume78.44 L7.17 L
52-Week High₹212.39₹2,422.3
52-Week Low₹132.3₹1,086.7
Distance from 52W High-16.57%-22.93%

Valuation

MetricPPLPHARMAWOCKPHARMA
Market Cap₹23,554 Cr₹30,362 Cr
P/E Ratio-75.43x144.46x
P/B Ratio3.01x6.23x
EPS₹-2.45₹13.1
Book Value₹64.78₹304
Dividend Yield0.08%0%

Growth

MetricPPLPHARMAWOCKPHARMA
Revenue Growth (TTM YoY)-0.1%26%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth-0.08%29.9%
Qtr Profit Growth-25%688%

Profitability & Leverage

MetricPPLPHARMAWOCKPHARMA
ROE-3.83%6.11%
ROCE2.52%7.55%
Net Margin-3.68%3.3%
Operating Margin10.4%19.3%
Debt to Equity0.7x0.45x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricPPLPHARMAWOCKPHARMA
Promoter Holding34.86%49.08%
FII Holding30.18% 0.52 pp7.09% 0.1 pp
DII Holding15.61% 0.08 pp10.96% 0.41 pp
Public Holding19.01% 0.34 pp32.83% 0.52 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Piramal Pharma Limited and Wockhardt Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.